Adjuvant IB-IIIA NSCLC Phase III Study of Nivolumab After NEW*** EA5142 Surgical Resection and Adjuvant Nivolumab vs (ALCHEMIST) Chemotherapy in Non-Small Cell Lung Observation Cancers PF-06439535 B7391003 Metastatic Non-Squamous Double-Blind (avastin biosimilar) **NEW** NSCLC PF-06439535 Plus Carbo-taxol Vs Bevacizumab Plus (reimbursed) Paclitaxel-Carboplatin Lymphoma Trial # Diagnosis Schema Drugs Provided Status Untreated Mantle Cell RB- R vs RBV R vs RB LR vs RBV LR Bortezomib; Available Lymphoma lenalidomide in July Open label Lenalidomide R-CHOP E1412 Newly Diagnosed Diffuse (R2CHOP) vs. RCHOP (Rituximab, Lenalidomide Available Large B Cell Lymphoma Cyclophosphamide, Doxorubicin, in July Vincristine and Prednisone) Myeloma Smoldering Multiple Lenalidomide vs Observation Lenalidomide Active Myeloma
EA5142 (ALCHEMIST) Adjuvant IB-IIIA NSCLC Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Nivolumab vs Observation NEW*** B7391003 Metastatic Non-Squamous NSCLC Double-Blind PF-06439535 Plus Vs Bevacizumab Plus Paclitaxel-Carboplatin PF-06439535 (avastin biosimilar) Carbo-taxol (reimbursed) **NEW** Lymphoma Trial # Diagnosis Schema Drugs Provided Status Untreated Mantle Cell Lymphoma RB- R vs RBV R vs RB LR vs RBV LR Bortezomib; lenalidomide Available in July E1412 Newly Diagnosed Diffuse Large B Cell Lymphoma Open label Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) Lenalidomide Available in July Myeloma Smoldering Multiple Myeloma Lenalidomide vs Observation Lenalidomide Active
Mt%20Sinai%20Cancer%20Research%20Trial%20List%20June%202016.docx